januari saw fy interim trade updat vectura sinclair abcam
clinigen dechra vectura announc re-focus effort gener capabl
addit cut spend help profit follow strateg review
sinclair trade statement saw revenu slightli forecast
guidanc reiter ebitda profit year howev tone key asset
silhouett us notabl cautiou given issu almiral clinigen interim
statement line ebitda despit under-perform due major
contract materialis
dechra interim trade unaffect recent issu seen peer virbac
report strong underli growth us later month dechra announc
acquisit ast farma le vet unlist gener gener plu develop
base netherland total consider abcam deliv strong
underli revenu growth minor fx headwind result move
outperform sector perform elsewher saw uspto rule
zytiga patent blow btg actual see larger risk
crofab potenti competitor launch end
regulatori level saw two updat hansa medic announc full
recruit investigator-l potenti pivot highd studi kidney
north american colleagu note celgen acquisit juno
therapeut diversifi pipelin post-revlimid bioverativ receiv
take-over bid sanofi addit saw report earli sign
stabilis gener sector potenti divest allergan busi unit
unlock valu
takeaway find document
takeaway month page
eu research valuat tabl page
month ahead trade idea page
versu consensu upcom result
newsflow us page
eu investor need know page
takeaway month eu healthcar research
januari event month sever compani coverag
report interim fy trade updat addit announc acquisit
regulatori updat dechra abcam announc posit interim trade
updat confirm convict respect long-term compound growth
stori vectura trade updat mix revenu line pipelin
asset spend cut help profit near-term clinigen interim trade
updat highlight good start commerci unlicens busi
qp ebitda line materi underperfom expect due
larger contract materialis dechra announc acquisit ast farma
le vet group unlist gener gener plu develop base
netherland total consider
elsewher saw uspto rule zytiga patent blow
btg make forecast chang actual see larger risk crofab
potenti competitor launch end
regulatori
level hansa medic report full enrol
investigator-l potenti pivot highd studi lead asset kidney
highlight eu healthcar research
indivior updat survey optimist sublocad
ahead sublocad launch survey physician build
physician survey link gain insight intend prescrib updat
known list price vs list price origin expect
encouragingli survey result suggest physician prescrib product
patient match data prior survey patient
ask physician provid
estim proport patient believ would receiv drug given
reimburs pressur etc figur reduc still think
enough support drug given higher price compar initi
exhibit survey question percentag opioid addict patient would use long act product
follow time period
patient prescrib sublocad proport believ
receiv drug physician view filter reimburs list price
averag percentag patient physician would use la product
month
sermo capit market estim
increasingli confid potenti sublocad given survey ii
delay iii delay gener film iv growth overal
market increas sublocad forecast off-set prudent
market share loss film higher cost see indivior push hard whilst
depot competitor market
indv film franchis note indivior film franchis retain signific
share market spite signific competit product variant
activ ingredi includ cheaper gener tablet even brand film
competitor share begin weaken indivior lose share cost
consciou nich market lower valu altern in-lin prior
guidanc believ expect investor
exhibit us opioid addict market script analysi buprenorphin contain product
script share buprenorphin contain product
suboxon film total market script growth note script
declin suboxon tab switch film
sotp spite strengthen sterl sublocad valu increas
offset weak elsewher see inflect point approach could
cement settlement reach remain gener see
remain risk enter think investor focu could
hansa medic ab investigator-l studi kidney transplant fulli recruit
hansa medic announc enrol us investigator-initi phase
trial assess lead asset highli sensitis kidney transplant patient
finalis total patient trial cedars-sinai medic
center professor stanley jordan princip investig involv patient
donor specif antibodi dsa posit cross-match test prior treatment
aim trial show igg-cleav enzym use reduc
level dsa patient turn cross-match posit neg
therebi enabl transplant procedur addit patient follow
period six month monitor safeti kidney function level dsa
hmed potenti pivot highd studi kidney transplant fulli recruit
hansa medic announc full enrol potenti pivot highd studi
refractori kidney transplant kt patient trial conduct five
centr us europ total patient treat lead asset
origin aim recruit patient line expect
see key clinic trial expect full result secondari
endpoint kidney function amr rate six month key like
juli compani intend submit bla kt like
launch still track manag guid launch date
prudenc allow small amount slippag think news taken
posit investor fix timet strongli
demonstr concept work kt patient includ highli
sensitis also utilis organ deceas donor continu see
peak sale kt set come indic
compani fulli fund deliv
mix trade updat revenu line pipelin asset spend
mix trade statement vectura compani refocus effort
gener capabl cut spend help profit near term clear
view today long-term impact compani lost product
revenues/opportun etc overal see rational refocus effort
given delay pipelin particular one could argu make
vectura attract asset potenti suitor focus player
gener space howev whilst cut benefit ebitda near term
long-term impact besid lost asset difficult assess today await
updat financi result expect march
abcam issu slightli stronger expect trade statement revenu
ahead underli report basi rais revenu
ebit ep outer year declin tax rate
beneficiari us chang move outperform sector perform consid
top-lin growth sustain henc upsid potenti like
bup peer transact support valuat
note us peer nyse sell haemostat agent
manufactur baxter up-front equat ltm revenu
baxter alreadi market lead asset floseal tisseel see acquisit
broaden baxter capabl haemostat space technic
price perspect recothrom much cheaper altern floseal tisseel
must appli gelatin spong less convinc data henc see
broaden bag product avail market
discuss show valu hard manufactur med-tech asset
liquid thrombin preveleak
establish player interestingli biomup complet pivot trial
hemoblast thrombin plu gelatin spong show superior efficaci
see news support biomup valuat mcap
cash arguabl better asset
dph ln us rude health caution wind
dechra report solid start trade statement show
revenu ahead expect na region continu sourc
out-performance growth cer think impress given
known headwind hurrican etc continu see dechra one best
compound growth stock coverag reiter op
clin potenti posit read across higher valu compar sourc market
note news today novarti
start phase post-
commercialis studi approv biolog cosentyx market lead
biolog humira also humira propos biosimilar biolog gener
adalimumab exceed surpass studi move novarti test
approv asset effect refer product propos
biosimilar new us see merit strateg perspect defend
grow share believ move could follow other think could
help drive higher growth compar sourc market given new
approach develop particularli valu biolog asset gener
multipl convent simpl molecul drug see clinigen busi
one could benefit direct read across clinigen today
certainli posit indic market
sph ln posit underli momentum caution us requir
light recent poor share price perform think today rn repres
opportun investor cautiou word us roll-out silhouett slight
miss revenu disappoint sph ebitda posit momentum clearli
build revenu gross margin grow share
simpli cheap
sph ellan brazil approv ahead schedul
sinclair announc receiv regulatori approv ellan anvisa brazil
month ahead expect brazil key aesthet market
inject procedur equat market opportun ellan
averag price syring see second import
regulatori approv newsflow asset perhap sinclair ex-silhouett
behind futur potenti us approv launch ellan forecast suggest
revenu brazil ellan gener today market
combin think news combin trade updat yesterday light
poor perform share sinc start year help continu
relief ralli seen share
clin ln trade line ebitda weather lumpi perform
clinigen rn highlight good start commerci unlicens busi
qp materi underperfom expect due larger contract
materialis spite ebitda line expect make
forecast chang whilst investor like focu note impli improv
earn qualiti profit ex-ct sustain grow
btg ln zytiga risk crystallis year caution
uspto rule zytiga patent blow btg us zytiga
royalti revenu assum gener make
forecast chang gener could come sooner alongsid risk crofab see
share close full valu advis caution earli stage im asset begin
indv sublocad peer product launch delay fda issu
indivior list peer camuru receiv complet respons letter
inject buprenorphin asset opioid use disord expect
approv decis sole competitor product indivior key pipelin asset
real detail within statement type key
question etc new trial complet us market partner
braeburn camuru work fda answer key concern think
minor delay mind initi thought launch
push back least year base upon say month answer question
resubmit ii six month review period like approv one would
thought plu iii month launch prep
roch contract win marque sign abcam insid
abcam enter exclus licens agreement roch take
recombin rabbit monoclon antibodi roch subsidiari spring biscienc
acquir roch research use market gather
spring bioscienc licens rabmab technolog epitom
acquir abcam believ rational deal abcam take
manufactur in-hous asset roch time plug
distribut platform like enhanc revenu growth potenti margin
abcam maximis return roch outsourc think deal make
good strateg sens abcam see posit share albeit materi
forecast upgrad may take time come
novarti result read across vectura
ultibro seebri revenu partner novarti came short
expect els equal equat miss ebitda
howev whilst disappoint see miss think
growth rate off-set concern futur growth thought asset
peak ultibro growth acceler constant currenc compar
year whole post posit flame flash data favour
gold guidelin updat forecast growth ultibro
look achiev henc materi impact forecast expect
sann neg chmp opinion reiter raxon
santhera announc oral explan chmp
ema relat re-examin market author applic
raxon idebenon duchenn muscular dystrophi dmd compani
anticip chmp maintain origin posit issu neg opinion
santhera file type ii variat exist market author
leber hereditari optic neuropathi lhon think clear neg
compani albeit expect mani given preced weak share price
sinc origin chmp neg opinion next event compani
us phase read-out product dmd could support file
us alongsid refil eu albeit need understand neg opinion
detail could relat us trial manag host call
friday januari provid detail
csrt sandoz novarti gener advair track
note novarti result present gener advair program
sandoz divis track outcom expect may see
neg consort manufactur devic vectura
out-licens hikma see surpris would caution
read much guarante launch given probabl first-
round applic given resubmit post major
confid approv time round product henc consort
cautiou vectura/hikma given fda disput resolut process on-going
sandoz launch first would neg consort vectura
say perhap earli say point
dph go dutch acquisit line strategi addit
dechra announc propos acquisit unlist european pharma
compani ast farma le vet beheer total consider
predominantli develop gener gener plu brand
gener cap product revenu equin fap
deal fund debt equiti split place balanc
share co look like sensibl deal complet line manag
state strategi dechra manag target compani
mani year
indv updat survey optimist sublocad
ahead sublocad launch survey physician gain insight
intend prescrib updat known list price increas
sublocad forecast off-set film market share loss chang gener
assumpt analys recent im trend seen market
share loss higher sell cost see indivior maximis delay
whilst risk remain think may overdon see inflect point
approach could materi turn investor sentiment investor focu
outlook market leader fast grow market rather past film
btg peer sirtex acquir valuat attract expect
btg peer sirtex medic acquir us peer varian mcap cover
us healthcar analyst brandon henri base factset forecast
deal equat ev/sal ev/ebitda pe multipl
respect compar favour btg
trade sale ebtida ep year
utilis ev/sal acquisit multipl seen sirtex would equat valuat
btg theraspher busi io divis includ
theraspher biocompat concept use chemotherapi galil
cryoablat busi valuat model
overal see valuat read across neutral btg io divis
arguabl near full valu overal think deal potenti neg
competit standpoint btg given product hand well-
capitalis peer consider experi target us hospit space
suit radiotherapi radiosurgeri proton therapi brachytherapi asset
market high growth perhap space one player
financi muscl perhap focu sir-spher could see
competit btg
healthcar valuat tabl sector perform chart
capit market estim factset price inform base price market close bst januari decemb denot act broker
companyrecupsideptpricemcapevforecast growthforecast growthforecast compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate spec spec medic aboutperform spec seknanananananananananananahorizon discoverysector perform spec biopharma outperform spec therapeuticsoutperform spec exclud shield salesev ebitdap eu healthcar
exhibit weight averag share price perform coverag versu ftse share
jan januari
jan januari
jan januari
jan januari
jan januari
jan januari
share exhibit coverag perform versu peer wider sector
jan januari
jan januari
jan januari
medicalnmc dechra pharmaceuticalscv groupeco anim groupindiviorabcamudg careclinigen groupgenusi pharmacaretech holdingsconsort medicalfts sharestoxx europ ehorizon discoveri groupastrazenecasmith nephewglaxosmithklinecambian groupbtgvectura groupshirebenchmark holdingssinclair pharmaspir care gp hikma pharmaceuticalscircassia medicalnmc dechra pharmaceuticalsindiviorabcameco anim grouphorizon discoveri groupcaretech holdingsi pharmagenusclinigen groupcv groupcambian groupudg carefts sharestoxx europ ebtgastrazenecasmith nephewconsort medicalglaxosmithklinespir care gp benchmark holdingscuretisshiresinclair pharmavectura grouphikma pharmacircassia medicalnmc dechra pharmaceuticalshorizon discoveri groupabcamcambian groupclinigen groupianc pharmaindiviorgenusbtgcaretech holdingsudg caremereo biopharma groupeco anim groupconsort medicalcv groupcuretisastrazenecastoxx europ efts sharesmith nephewcircassia pharm convatec groupglaxosmithklinebenchmark holdingsspir care gp shirevectura groupsinclair pharmashield therapeuticshikma pharmavernali month ahead trade idea
look februari interim result dechra clinigen well
convatec indivior result term regulatori newsflow watch
updat cureti applic unyvero devic potenti feedback
fda hansa medic track statu lead asset phase
top line result mereo aromatas inhibitor obes men
go result post profit warn trade statement
look updat follow key question organ growth rate
year whole ii updat supply-constraint issu woundcar ostomi
iii mip implement importantli iv guidanc
trade updat full-year organ revenu growth reduc
low end guidanc suggest neg organ due
woundcar ostomi supply-constraint issu transfer manufactur
haina led lost order issu within awc ostomi worri
see knock-on impact custom switch perman lower focu
selling/new busi focu meet guidanc lead pull futur
demand hit whilst manag chang outlook mip
target see specif risk sinc origin target set
expect rise volum impact supply-constraint issu
ostomi awc
indivior result look updat result market share
develop ii updat gener risk iii launch prepar recent
approv inject depot asset iv guidanc
result link saw margin miss top line estim
due increas competit us within lower cost portion
market plu tough comp due stock profit line lower legal
cost guidanc reiter top line
adjust pat indv deliv sep
interim trade updat link saw impli revenu european
pharmaceut divis came
forecast respect total revenu ahead forecast
interim result look inform impact recent us
corpor tax chang could lead small upgrad ep forecast
tax rate arguabl could come lower addit sinc
dechra announc complet small bolt-on acquisit rxvet new zealand
interim trade updat keen hear acquisit plan
also see pipelin launch set new subsidiari either organ
acquisit catalyst dechra compound growth stori
interim trade updat show good start commerci unlicens
busi qp materi under-perform expect due
larger contract materialis
look detail integr quantum pharma immc
particular near-term movement pipelin ii integr
link knowledg base progress iii roll-out cliniport
potenti catalyst timet coverag coverag peer
exhibit potenti catalyst timet coverag coverag peer
compani inform factset estim note indic project result releas date
stockfebruarychaprilabcam result feb horizon discoveri capit ket day feb biorad result feb result merck kgaa result result feb integra lifesci result feb result feb medic solut result ergom result trade updatecircassiagsk result feb preliminari result ch result feb pharmaceut result result feb gerresheim feb recipharm result feb trade updateconvatec coloplast result feb result feb smith nephew result feb convatec result feb feb result feb advanc medic solut result result feb interim result feb result ch vetoquinol ch medicalhorizon discoveri result feb capit ket day feb biorad result feb kgaa result result feb camuru result feb result tbc result tbc updat drl gener alvogen court casemereo biopharmashield result feb pharma result ch pharmaallergan result feb almiral feb preliminari result tbc vectura gsk result feb pacira result feb disput resolut fda gener advair potenti re-submiss timelin preliminari resultsclear decis fda unyvero devic result tbc qiagen result jan biomerieux result feb diasorin result top line result oral aromatas inhibitor develop obes men hypogonad hypogonad result feb feedback fda meet track statu argenx result ch
versu consensu upcom result
exhibit versu consensu compani report soon note consensu expect may small number contributor
factset capit market estim note highlight limit consensu data
stockmetricconsensu fcst fcst fcst june year june year june year sinclair pharmavecturaconvateccureti dechrahorizon discoverybiom clinigen newsflow item north america
divest unlock valu
neutral view
persist
wholesal face
comparison
colleagu north america note follow key theme januari
deep dive report divest differ busi unit allergan unlock
valu sign gener stabilis acceler
shield peer
athenex cfda approv
oraxol trial china
posit read across
larg cap pharma turn
larg acquisit
randal stanicki publish three deep dive report allergan analys potenti
divest women health gi anti-infect busi divis
option unlock valu allergan share suffer challeng
view neg revis loss exclus loe pipelin
disappoint randal see meaning better set-up think
activ portfolio management/asset sale remain theme instanc sale
non-cor anti-infect busi would smart strateg step send
strong messag investor
randal stanicki team spoken sever public/priv manufactur
assess industri trend gener sector whilst team neutral view
sector close two year hold cautiou stanc main topic
elev price eros level volum fda approv activ exist gener
headwind irrat competit behaviour call altern distribut
persist georg hill work gener drug price show base increas
gener volum decreas price decreas brand script wholesal
face tough gener drug price comparison entir calendar year
kennen mackay report posit result akebia japanes phase
trial vadadustat inhibitor prolyl hydroxylas regul express gene
requir iron metabol dialysis-depend chronic kidney diseas patient
announc chines fda cfda accept recent ind
applic oraxol oral paclitaxel start clinic trial china paclitaxel
frequent associ cardiac toxic henc think on-go clinic
studi paclitaxel read-across clinigen asset cardioxan
indic cardiac toxic reduc incid sever cardiomyopathi
associ doxorubicin administr women metastat breast cancer
receiv cumul doxorubicin dose continu
receiv doxorubicin therapi maintain tumour control
brian abraham report celgen acquisit
view unsurpris strateg import step maintain long-term
haematology/oncolog leadership accord model accret begin
despit high price believ deal diversifi celgen around
revlimid patent cliff acquisit alongsid intern pipelin progress improv
commerci execut improv sentiment drive upsid kennen mackay
analys sanofi bid bioverativ spec pharma compani focus rare
blood disord gain foothold alreadi competit haemophilia market
think strateg valu deal albeit high price
exhibit stock cover dougla miehm
titl link note
littl new inform confer look
guidanc report
medic facil form joint ventur
acquir seven asc
improv miss
medic facil deliv acquisit
remain weari multipl paid
shpg get fda nod technolog transfer
cinryz manufactur austrian site
nvln plan cut cost review capit
structur light headwind
announc co-commerci strategi
north america geting
shpg provid updat review neuro segment morn shire provid updat strateg review
neurosci divis compani indic creat two distinct busi segment diseas
neurosci divis shire initi announc consid spin-off neuro segment time
lack new inform set stage guidanc report vrx ceo papa spoke
investor confer earlier today surprisingli littl new inform given releas
document yesterday morn guidanc provid come result compani
continu emphas turnaround cite recent event debt reduct settlement allergan litig
outlin interest relev piec inform releas present
ventur acquir seven asc close friday medic facil announc form joint
ventur jv llc acquir seven asc meridian surgic partner jv term mfc
nueterra hold compani llc major own dr total transact valu seven asc amount
dr indic portion undisclos would fund cash hand draw credit
facil jv equiti interest stake center transact expect close
result gener better anticip consolid revenu beat
estim gross margin also stronger estim note beat top-lin
margin driven non-ffr medic revenu though ffr revenu show sign improv
believ medic facil majority-own jv could benefit compani strateg perspect provid
foundat futur growth space investor like wait dr complet
acquisit believ multipl paid ev/ebitda higher expect
fda grant approv technolog transfer cinryz product morn shpg announc fda grant
approv technolog transfer cinryz drug product manufactur process site vienna commerci
manufactur drug vienna begin addit continu manufactur
novelion announc cost reduct capit structur review today close nvln announc
undertak signific cost reduct measur perform capit structur review releas cite disappoint
financi perform current cash posit expect cash usag uncertainti due
aegerion doj sec investig reason behind plan
geting agre co-commerci north american strategi announc enter new
agreement geting term sale repurchas agreement term agreement
abl sell associ product directli us canada repurchas less
steril geting initi order unit beyond steril repurchas
geting continu sell inventori north america rest world morn releas also note
origin exclus distribut agreement parti expir august extens
agre geting must repurchas remain steril unit price
sale repurchas agreement juli
geting deal suggest entri transit
period downgrad sector perform
pli final design ph studi pbi-
ipf follow fda meet
earlier today announc enter new co-distribut agreement geting allow
sell directli us canadian market although long-term view compani
posit downgrad sector perform specul risk sinc believ new develop introduc
sever unknown near term
pli final studi design ph trial morn promet announc outcom success
type meet fda held jan purpos meet final design
ph pivot clinic trial patient ipf
exhibit stock cover randal stanicki
titl link note
sector si flat mix focu move
cost cut via import
expect step ahead meet next week
thought
rais pt ahead expect pre-
announc question meet
deep dive gi could worth
model revisit break-up focu continu
pre-announc consensu
traction take hold acceler
growth dec
remain known top idea
model link research
top idea cross-sector theme
potenti surpris
sector short interest exhibit period end flat rel prior period somewhat mix
took closer look agrx also highlight move si move higher
follow previou move last period ii si
announc intra-day via undertak cost cut restructur program elimin
fill posit open posit save expect million million rang
compar bottom line posit step one expect announc
would pursu cost restructur off-set pressur loss exclus enabl
achiev non-gaap perform ep level outlin call ep floor earli gener restasi ep
floor mid-year word believ cut larg bake expect
rais target ahead expect pre-announc week importantli
breakfast ceo dave stack monday breakfast expect discuss potenti chang
around unbundl payment could repres game chang opportun exparel bottom line reiter
op rais target continu momentum ahead
share juli high fundament headwind persist larg cost restructur
announc yesterday help near-term still see long-term valu could unlock via sale matur non-
core asset report drill gi busi anoth candid divestitur follow
deep dive women sever model chang target
morn report preliminari revenu million revenu million net
exparel sale million year million came modestli ahead consensu
million key updat press releas commentari around partnership
drive ramp ramp exparel sale notabl dec us suggest
solid momentum enter help add comfort around outlook current consensu
revenu growth traction still pick bottom line think momentum
stock continu reiter op rate
leav behind challeng follow challeng somewhat improv
set-up last coupl year remain select see pocket potenti meaning out-performance
within brand specialti drill five broader sector theme one-pag stock tear sheet
past sever day held call major cover compani get sens
could see potenti surpris ii like pre-announc provid earli color iii
could see possibl chang tone outlook recent conferences/meet also provid link
read and/or help recent research report model cover compani
exhibit page help late confer prepar
healthcar sector ahead despit moder perform
rel broader market exhibit within healthcar perform hcit med-tech
outperform move team bullish med-tech
titl link note
four import theme upcom
meet ipxl/amn manag
new ceo final announc bring
closur seven month search
preliminari guidanc surpris
abil unlock valu encourag
spend time week manag ipxl/amn discuss newco compani
broader environ meet time import come ahead deal close expect
investor earli question whether gener landscap may improv overal four primari
theme look get better color around
morn announc appoint uwe rohrhoff new ceo board member one
top potenti surpris discuss last week healthcar outlook mr rohrhoff
year experi gerresheim ag manufactur pharmaceut packag product
medic devic recent serv ceo retir aug replac
outgo ceo john hendrickson announc retir jun
host breakfast meet morn manag follow ensu meet
includ ceo dave stack bottom line come away feel separ exparel j-code like
traction relationship continu potenti broaden focu high upcom nerv block panel
continu effort provid better clariti around outlook updat ep floor introduc revenu
guidanc latter one surpris call week updat gener line buysid
mix street consensu interest pr commentari point abil unlock valu near/long term
break-up/asset sale thesi remain unchang support upsid case
thought new amneal/ipxl post
manag meet broader takeaway
host larg breakfast meet ipxl/amn manag includ paul bisaro bryan reason
ipxl side chirag patel amneal three broader takeaway becom increasingli posit
stori ii industri trend seen stabl iii ipxl strategi evolv like shape
near-term catalyst potenti
meaning move stock rais price
target
revisit model outlook kmph meet manag last week bottom line
met host compani sf kmph stood given magnitud upcom catalyst small cap stock
larg radar rais price target model updat meaning upsid option
becom better understood near-term
earli support gener
near-term recoveri unlik trend
stabil support neutral view
assess catalyst path
follow meet manag
 set-up attract anti-infect
past two week spoken sever public/priv gener manufactur discuss industri trend
coincid shift view neutral view sector follow close hold cautiou
stanc detail outlook report report summar four import takeaway earli year
meet specif manag commentari last week detail page also continu monitor
five trend first identifi oct link precursor revers headwind see soft
land rel stabil understand headwind remain rel posit ipxl becom
increasingli interest hold pipelin option teva downsid potenti remain
follow meet manag updat model reflect anticip pipelin updat
year overal make sever model tweak pipelin progress believ stock perform go
depend sever import updat year investor question around need strateg pick
chang outlook price target
messag help de-risk outlook head past guidanc uncertainti
 set-up better key pipelin updat get closer continu see potenti unlock valu catalyst
report look potenti sale non-cor anti-infect busi favor messag could
bring chang outlook
titl link note
gener articl non-profit hospit
group creat gener drug compani
headlin rais
specialti pharma
focus week
focus week
bull/bear debat ahead guidanc stori
stock trade turnaround invest
soft consist guidanc impli
gener pharma sandoz big focu nv
call sever key takeaway
new york time publish articl suggest group larg non-profit hospit plan go
drug busi receiv steadi incom call given group weak morn bottom line
would care read much near-term risk see headlin come
strong move earli year group said continu look broadli evolv industri
dynam serv remind us room structur chang addit vertic integr
and/or pool purchas part market drive margin save cost consortium done
one less talk understood possibl
head next week fresh investor meet domin inquiri around set-up
think improv ii teva focu shift upcom guid date still see stock risk last
week also remind us solid gener sector start year group versu still prone
headlin volatil given late week weak hospit articl matter expect nv
india report ie dr reddi clear remind headwind still impact think
get materi wors final road week meet investor
teva new ceo done solid job make tough decis commun aggress straightforward
plan street turnaround enthusiasm reflect stock sinc chang leadership
ensu cost cut announc outlook like drive stock upcom guidanc feb
remain cautiou take look bull/bear debat set-up
approach
close region competit cross-read top india-bas gener billion usd
versu gener coverag billion perspect
cap similar nifti pharma
nvs/sandoz set tone gener earli tomorrow morn
even dr reddi thursday morn bring earli import gener sector data point
india-bas gener manufactur continu
india-bas biocon follow
earli morn nv report includ sandoz perform metric sandoz receiv signific
attent last sever month given size also given soft result announc us plant closur potenti
divestitur gener dermatolog busi per press report overal expect low show
gener consist result prior weak us result global sandoz price eros consist
last quarter quarter mostli us us sale due industry-wid
pressur continu custom consolid bottom line first read ahead call result combin
guidanc point anoth similar year sandoz flat slight declin suggest headwind expect remain
unlik get materi wors consist view sector
sandoz focu notabl high nv confer call morn provid lot import us gener
cross-read sector also cross-compani ie teva data point detail initi thought
morn earli gener read-through sandoz us soft consist guidanc impli
base earli morn investor back forth overal result view two way glass
somewhat half fuller result weak gener consist outlook impli similar flat slightli
result ii glass half empti anoth challeng us erosion/sal result guidanc impli
continu read result consist evolv view sector headwind signific
abat get wors point much better understood consist
neutral sector view
titl link note
thought long thesi
call volum focu high parallel ytd move drg much gear
upsid case uncertainti way loss exclus concern better understood
set-up improv sotp valu remain next leg link import recur question
still need address
gener pharma read earli india
earn call takeaway dr reddi
biocon call big focu gx copaxon
biocon dr reddi report fiscal earn ensu earn call late last night morn dr
reddi provid better read na gener total revenu compani call import
takeaway cover gener well sector color compani call us price pressur channel
consolid press releas becom expect gener disclaim thought tone
rdi call somewhat better fiscal call last quarter come sizabl miss
stock abil hold line
revenu drill line line
feb guidanc draw near focu teva recent meet ramp consider cost cut debat
behind us given perceiv credibl billion target discuss center specif revenu
level teva hold beyond think multi-year horizon focus
view drive stock
meet investor last week road meet investor week clear
focu remain two name whether ytd move go stall get
cgrp /pipelin date see recent note drill question get link ii teva buysid focu
high around revenu number teva support revisit model weekend
compar consensu determin differ detail separ report also publish
morn link think next week specialti pharma much calm earn
storm teva kick thing februari though listen color call
dial-in report follow week provid
thought around question heard investor meet last week
earli launch survey orthoped surgeon look initi color around zilretta knee
osteoarthr oa pain anticip awar still build patient feedback limit physician interest
product high think launch track set one best month stori
coverag reiter outperform specul risk
morn announc fda classifi outcom reinspect mcpherson
kansa facil voluntari action indic vai believ glatopa like approv
launch come surpris follow sandoz recent commentari link indic launch
partner bottom line could bring new gener copaxon player market sooner
expect repres earlier competit pressur teva under-perform brand player sector
perform gener player ahead guidanc introduct
specialti pharma
focus week
focus week
earn storm question
hear focu high teva
feedback survey expect
generics/copaxon facil move
vai statu competit teva/myl like
come earli mnta/nv
exhibit stock cover glenn novarro brandon henri
titl link note
key stock price appreci
share trade discount peer make attract valuat standpoint howev
share close valuat gap versu sector believ manag must deliv consist mid-
pharmaceut segment look end
high note thought
pharma becom growth engin sale five mega-blockbust manag
highlight may investor day gather momentum pipelin also progress despit
setback new product indic contribut pharma growth year rais price target
reflect shift base year valuat
fundament foundat upgrad top
upgrad share top pick outperform price target think share offer best
risk/reward balanc within large-cap coverag fourth quarter earn due februari like posit
catalyst elimin concern around guidanc afflict share sinc compani announc
anoth delay lotu edg
faster growth await rais price
target
product approv brighten prospect medic devic addit alr launch
alin diagnost platform market growth establish pharmaceut recoveri
pediatr nutrit growth driver price target move
medic suppli devic outlook
retain bullish view medic suppli devic sector convict base three observ
first continu find sector attract valu large-cap med-tech trade in-lin despit
superior growth mitig risk sector-wid sell-off respons unexpect company-specif neg
event second consensu estim reason formal guidanc unlik deviat far
consensu third recent channel check proprietari survey attend medic confer meet
manag team support belief end market cardio ortho capit equip remain stabl
respect volum price
retain bullish view medic suppli devic sector convict base three observ
first continu find sector attract valu large-cap med-tech trade in-lin despit
superior growth mitig risk sector-wid sell-off respons unexpect company-specif neg
event second consensu estim appear reason formal guidanc unlik deviat far
consensu third recent channel check proprietari survey attend medic confer meet
manag team support belief end market cardio ortho capit equip remain stabl
respect volum price
pre-announce revenu slightli street expect lower preliminari
adjust ebitda guidanc announc revenu result slightli street expect
morn announc preliminari result provid updat thought preliminari
outlook compani expect preliminari revenu fce preliminari full year
revenu y/i constant currenc rbce line guidanc previous
revis lower manag note prior assumpt intern revenu growth
linger impact hurrican maria puerto rico softer procedur volum continu
remain unchang compani provid commentari non-gaap oper margin unlik
pre-announce overal believ result may disappoint investor
view manag previou revenu guidanc conserv
question
med-tech manag
titl link note
ktwo announc preliminari
releas preliminari revenu expect adjust ep high-end guidanc
announc preliminari result morn manag expect revenu
manag guidanc beat consensu rbce vs fce
revenu increas compar revenu strong result driven
out-performance codman derma higher-than-expect organ growth improv perform
dural repair revenu beat manag guidanc rang rbce
vs fce impli revenu repres increas compar revenu
preliminari sale exceed expect strength upper extrem offset weak
lower extrem preliminari sale exceed expect morn announc
preliminari sale fce y/i constant currenc rbce recal result
includ benefit extra four busi sell day compani estim
note manag previous estim benefit four extra sell day overal
better expect upper extrem perform higher benefit four extra sell day
off-set weak lower extrem
ktwo releas preliminari revenu revenu
slightli consensu ktwo announc preliminari morn earlier today manag releas
preliminari result revenu rbce vs fce y/i
constant currenc basi domest sale expect rbce
y/i us complex spine expect increas y/i rbce line estim us
minim invas surgeri mi expect grow y/i rbce impli beat
estim us degen expect grow y/i rbce repres beat
estim revenu rbce y/i repres beat
compar forecast
announc preliminari result morn earlier today manag releas preliminari result
revenu rbce vs fce increas y/i y/i increas constant currenc
basi orthoped revenu rbce vs fce increas y/i rbce y/i
increas constant currenc basi fourth quarter instal mako robot global
contribut us knee sale growth y/i medsurg revenu rbce vs fce increas
y/i rbce constant currenc neurotechnolog spine revenu rbce
vs fce increas y/i rbce constant currenc domest sale
rbce y/i increas intern sale rbce increas y/i y/i
increas constant current basi
preliminari result goal demonstr underli strength three
segment diffus concern around compani abil sustain revenu growth market
peer lower tax rate year improv long-term growth profil reiter top pick
recommend price target
pre-announce better-than-expect revenu procedur growth believ procedur guidanc
like prove conserv pre-announce preliminari full-year result specif
pre-announce non-gaap revenu y/i rbce fce overal
believ report better-than-expect quarter top line driven primarili higher instrument
accessori system revenu
attribut neuromodul busi
titl link note
manag make case
turnaround pain therapi
nan analyst brief manag detail credibl plan return pain therapi busi unit within
restor therapi group growth target revenu growth thereaft pain therapi
estim await result accompani manag commentari
make adjust forecast
neuromodul carri momentum supplement new product db
portfolio posit busi meet possibl exceed sale perform y/i addit fda
approv expect late help sustain double-digit growth light manag upbeat
commentari sale estim neuromodul y/i may conserv
disappoint year given slow spinal implant share gain drop-off biolog
busi manag departur remain show-m stori believ guidanc
set conserv see valu share would long-term buyer recent pullback
result offer read-through ortho spine
surgic volum
revenu line guidanc better
rel estim
maintain outperform specul risk rate given best-in-class product portfolio extrem one
fastest grow orthoped market howev lower estim manag could give
us qualit evid suggest sale benefit new lower extrem rep also lower
price target impli sale ratio
ir issu notic provid temporari administr relief medic devic manufactur regard
medic devic excis tax intern revenu servic ir releas notic provid guidanc
relat medic devic excis tax specif notic provid relief first three calendar quarter
medic devic manufactur produc import failur deposit penalti provid
taxpay meet certain requir normal rule correspond regul appli respect
deposit due fourth calendar quarter thereaft notic intern revenu
bulletin irb publish februari
large-cap med-tech stock made promis start posit updat decemb quarter
sever compani year first health care confer favor impact cut corpor tax rate
extend ralli large-cap med-tech market-cap weight index large-cap stock
ew appreci first three week compar increas
 med-tech index exclud ew trade premium versu in-lin three
better-than-expect guidanc could give share lift near term revenu exceed forecast ww revenu
forecast consensu oper sale growth includ
bp acquisit net divestitur currenc favor impact quarter sale
pharmaceut consum segment match estim medic devic sale exceed estim
geograph oper growth revenu revenu
md revenu came consensu world-wide md sale fce surgeri
cardiovascular vision came better offset weak orthoped diabet exclud
acquisitions/divestitur world-wide md busi y/i easi comp vs
past quarter exclud acquisitions/divestitur md busi y/i vs
past quarter manag preliminarili estim overal hospit admiss flat y/i
vs surgic procedur y/i similar
titl link note
strong result rais price
execut continu improv
rais price target follow strong result manag continu make progress
order revenu convers front america perform continu lag manag optimist
recent hire drive improv america perform
share repres attract valu current
revenu estim
guidanc demonstr strength
believ yesterday sell ignor two import valu driver share long term pharmaceut
segment perform balanc sheet pharmaceut growth acceler new approv
expect year earli help mitig impact gener competit jnj strong balanc sheet
give manag ampl flexibl pursu share buy-back supplement organ growth
four segment exceed forecast lower gross margin higher sg mitig ep upsid revenu exceed
estim consensu report ww revenu y/i compar
basi revenu increas signific improv growth report
revenu increas diagnost medic devic segment two biggest sourc upsid compar
estim non-gaap ep high end guidanc rbce consensu lower gross
margin vs rbce higher sg expens revenu bp higher estim
product cycl refresh medic devic diagnost cost synergi stj alr capit deploy
acceler debt repay push abt revenu ep growth ahead sever med-tech peer
share reward premium valuat manag optimist tone strength portfolio
suggest top half guidanc realist rais pt
report better expect result owe partli strong execut rais revenu
non-gaap ep guidanc world-wide radiat oncolog market growth strengthen believ
compani continu gain near-term share elekta
continu make progress regard remedi north campu separ fda recent inspect
issu new form west campu eight observ form letter
west campu appear much less oner origin form letter compani north campu
overal continu aggress spend acceler develop work sever pipelin technolog
expand allow compani remain premium player surgic robot market despit
new/upcom competit rais estim price target move higher
earn week orthoped tuesday
ew report thursday
kick busi week med-tech earn tuesday morn guidanc focu tuesday
close lotu tax rate overhang remov guidanc next result expect
in-lin consensu despit hurrican spillov tavr growth key ew stock appreci
guidanc sell-sid expect howev believ leadership chang unlock
long-term valu report top-line beat ep line consensu announc
revenu guidanc fce y/i constant-curr basi guidanc
rbce geograph basi america sale fce y/i rbce
emea sale fce y/i constant currenc rbce asia pacif sale
fce y/i constant currenc rbce adjust dilut ep within
manag guidanc rang fce adjust gm fce separ
oper expens ratio slightli higher expect fce
titl link note
expans radioembol market
sirtex medic surpris
overal believ acquisit sirtex medic make strateg sens although deal price
cheap acquir sirtex medic australian compani intervent oncolog space morn
market open announc agreement acquir outstand share sirtex medic
cash premium repres total equiti purchas price base factset
forecast deal price cheap repres ev/sal vs closest competitor btg
ev/ebitda vs btg howev deal surpris previous written
could expand presenc intervent oncolog space like target
radioembol part market manag expect sirtex medic deal close may
deal accret ep first full fiscal year transact close
exhibit stock cover frank morgan
titl link note
news nashvil
weekli perspect healthcar industri
compani news valuat updat
outlook sector oper trend
highlight week end decemb sector price perform last week year healthcar
servic stock outperform broader market health servic select index spsihp
downtick versu declin strongest-perform subsector acut
hospit gain versu gain prior week manag gain averag vs
gain prior week ambulatori surgeri weakest-perform subsector last week
healthcar servic investor drain yearjust think endur new presid
immedi attempt repeal replac un-wind aet/hum antm/ci deal
string self-induc integration/oper blowup sever provid amid year-long backdrop weak
demand cours own manag great year medic trend continu moder
mco beat rais throughout entir year
encourag updat provid evhc suggest progress improv oper
welcom investor follow capitul sell-off novemb
influenza-lik ill
patient visit week
primer packag healthcar servic
news nashvil
weekli perspect healthcar industri
compani news valuat updat
preliminari ebitda look solid
instanc influenza-lik ill increas patient visit week flu season
decemb prior week remain well nation baselin chart
illustr accord cdc weekli influenza surveil report nationwid week end
decemb week flu season patient visit due influenza-lik ill ili
exceed nation baselin level
healthcar investor confer season kick provid comprehens review oper
trend issu across healthcar servic subsector coverag univers use
highlight week end januari sector price perform first week healthcar servic stock
under-perform broader market health servic select index spsihp gain
versu gain strongest-perform subsector institut pharmaci
gain acut hospit declin versu gain prior week manag gain
averag vs gain prior week healthcar reit weakest-perform subsector last week
believ explan declin appear reason volum remain solid manag
preliminari ebitda rang bracket current estim base histor perform would
surpris see initi guidanc prove conserv howev free cash flow expect yoy
disappoint explan seem reason opinion encourag see continu solid
trade-off earli monday like reflect market expect signific us healthwork synergi captur
see manag conservat despit market reaction select initi guidanc
earli trade monday manag outlook includ assum februari close us healthwork appear
reason compar pre-deal estim consensu market disappoint number like due
signific assum synergi captur year one
titl link note
 takeaway investor confer
 takeaway investor confer
 takeaway investor confer
ci key takeaway investor confer
 takeaway investor confer
lpnt takeaway investor confer
 takeaway healthcar
takeaway investor confer
execut chairman ceo ronald rittenmey present investor larg focus talk oper
initi drive growth reduc cost uspi conif valuabl asset uspi strateg
conif strateg manag conduct thorough due dilig buyer given compani
import cash cycl partner note manag sensit price first consid
sale rule spin conif
chairman ceo joey jacob presid brent turner present investor healthcar confer
focu overal behavior health market landscap uk compani de novo jv growth
revenu ebitda bracket estim adjust ep slightli
recent updat estim assum tax rate tax reform legisl manag preliminari ep
guidanc assum tax rate rel model higher tax rate slightli off-set lower share count
guidanc
manag expect earn growth consist long-term target exclud pyd
supplement growth capit deploy total ep growth outlook assum
revenu custom growth deepen custom client relationship leverag expens
combin addit impact wareh capit continu expect ep
integr care core compon strategi engag member greater
demand benefit build capabl central strategi compani bring togeth primari
home-bas care behavior health drug benefit wrap around member manag
whole health diseas progress integr among part healthcar system make impact
evidenc lower higher qualiti score higher net promot score hum virtuou circl integr care
reinvest save gener valu member build membership build clinic capabl drive qualiti
improv lead long-term ep growth
payor mix shift headwind manag medicar repres total medicar revenu
total revenu ytd manag medicaid total medicaid revenu ytd revenu
manag care percentag significantli larger histor level
hit cylind challeng earlier year complet implement
homecar homebas significantli reduc sale forc vacanc rate
compani return solid growth realiz annual cost save project
deliv goal achiev clinic distinct agenc rank star
enter person segment import manag care payor given larg number patient
chronic co-morbid continu bring voluntari turnov
demograph trend favor busi line behavior health side incid mental diseas
continu rise stigma declin acut busi age popul demand driver
number fast-grow market la vega california econom recoveri market
also help drive volum growth testament strength market revenu growth acut
busi rang even full impact econom recoveri bake make
comp challeng manag see reason cant continu outperform acut care peer
top-line growth note market grow faster market countri
titl link note
takeaway investor confer
multipl opportun lt margin
industri occup remain soft expect
influenza-lik ill remain flat
level past year
impress momentum new year
add jan aet show
strongest growth among
influenza-lik ill increas sharpli
week
hospit jv partner strategi key lhcg growth strategi roughli total volum revenu come jv
partnership within come directli hospit remain come
commun compani oper complet local brand patient employe servic
appear hospit partner leverag hospit brand reput jv approach
also advantag hospit provid custom solut continu focu patient care qualiti
outcom comprehens complianc improv oper financi perform vs in-hous
oper lower avoid hospit day keep patient hospit network
meet investor relat svp dominik heger director robert adolph nyc sinc novemb
ndr fm confid level near- long-term margin expans opportun increas base
meet yesterday
averag industri occup yoy slight deceler rent growth take-away
consist recent quarter overal occup senior hous industri remain soft rate growth
continu deceler occup like remain pressur near term due recent futur new
offici warn flu season could particularli sever prove true thu far activ larg
track similar trend follow two consecut season weak activ recal flu activ
headwind senior hous industri given neg impact flu resid censu senior
live facil acut care hospit flu activ optic issu volum may increas due higher
ili-rel visit ed visit admiss howev lower-revenu lower-margin busi
post anoth impress perform highlight strong growth across diversifi busi line
particularli medicaid risk-bas product optum servic dialog focus primarili expect
impact tax reform fact underli busi trend remain strong solid revenu earn
growth enhanc acceler invest growth rais pt
releas medicar advantag part enrol data januari ad member
roll sinc decemb bring total enrol note januari number reflect
larg bolu new member open enrol membership country-wid increas sinc
januari last year reflect increas penetr medicar advantag membership among medicar elig
popul medicar part enrol uptick sequenti increas sinc januari last year
return one compani major pe partner board make interest time announc
yesterday mike michelson senior leader pe firm kkr appoint board independ
instanc influenza-lik ill increas sharpli patient visit week flu season
januari follow flat level week chart follow page illustr accord
cdc weekli influenza surveil report nationwid week end januari week
flu season patient visit due influenza-lik ill ili far exceed nation baselin level
titl link note
news nashvil
weekli perspect healthcar industri
compani news valuat updat
short-term spend bill look posit
kick hospit earn season
tuesday would expect conserv
flu case acceler highest
seven year
news nashvil
weekli perspect healthcar industri
compani news valuat updat
sector price perform week end januari healthcar servic stock outperform broader
market health servic select index spsihp gain versu gain
strongest-perform subsector skill nurs gain versu gain
prior week acut hospit gain versu gain prior week senior live weakest-
perform subsector last week
govern chang anoth step toward flexibl strateg option morn file announc
board director approv amend corpor bylaw provid mechan wherebi
stockhold own major share request special meet stockhold
take-away view senat deal short-term spend bill posit reauthor chip delay
unpopular tax impos obamacar senat bill fund feder govern februari
expect pass quickli hous sign law presid trump would reauthor children
health insur program six year recal import program provid minor
coverag even parent health insur oper nearli four month without budget
state expect run money februari
take-away hospit result show sequenti improv disappoint would
anticip conserv guidanc new year apart posit benefit tax reform healthcar
nyse kick earn season publicly-trad hospit univers tuesday morn
adjust ep adjust ebitda slightli within consensu
expect respect follow disappoint perform five six
public hospit compani report result expect due partli impact hurrican expect
sharp sequenti improv
instanc influenza-lik ill increas patient visit week flu season januari
chart page illustr accord cdc weekli influenza surveil report
nationwid week end januari week flu season patient visit due
influenza-lik ill ili prior week far exceed nation baselin level
sector price perform week end januari healthcar servic stock under-perform broader
market health servic select index spsihp gain versu gain
strongest-perform subsector temporari staf gain acut care hospit
gain versu gain prior week manag gain versu gain prior week
skill nurs weakest-perform subsector last week
 initi quarterli dividend
improv result strong cash flow
guidanc
nyse post strong finish year improv disappoint result
exceed expect better oper trend particularli higher-acu inpati servic line believ
encourag initi guidanc ahead consensu
exhibit stock cover brian abraham
titl link note
earn preview
upgrad op clinic regulatori commerci
prospect improv
downgrad sp stock better reflect hcv
royalti growth pipelin prospect
downgrad sp platform portfolio promis
upgrad op reward/risk epacadostat ph iii
ms price hike could provid lift potenti
upsid est
earn around corner compani expect pre-report next week provid
thought select larg mid-cap biotech compani within coverag earn guidanc
preview celg addit look consid recent develop
current stock valuat upgrad outperform upgrad outperform specul
risk downgrad sector perform downgrad mru sector perform specul risk
upgrad outperform specul risk sector perform specul risk increas
target remain confid activ market cap appear
reflect increas unmet need oral altern likelihood ph iii success low regulatori bar
see attract entri point
downgrad sector perform outperform posit near-term thesi hcv
growth fxr pipelin progress gener play expect share trade in-lin
broader sector come year
downgrad mru sector perform specul risk outperform specul risk
remain enthusiast long-term promis bispecif antibodi pipelin platform share
appreci late point see fewer potenti near-term upsid driver share
lead program portfolio matur adjust price target
upgrad outperform sector perform maintain target
share consider high exist products/pipelin help place floor share believ
reward/risk go epacadostat ph iii data improv substanti see buy opportun
ahead event
price increas ms portfolio post provid earli view price approach
move larg consist price hike seen could provid potenti upsid
price growth estim conserv model net price pull fulli realiz maintain
highlight key fda ae report drug coverag
increment updat glpg cf program
price detail approv gene therapi reveal
even glpg provid mostli increment updat cf program multipl shot
goal promis asset like continu believ area pipelin filgotinib ipf may
provid interest valu driver respect continu believ difficult glpg
catch lead cf develop commerci see opportun addit appreci
year data potenti expedit path het/min patient tez/iva launch
morn detail price reimburs structur luxturna suggest industri key
constitu reason align initi approach tackl inher challeng gene therapi
administr -- posit indirect read-through avx though continu view avx fairli valu adjust
tgt model updat
titl link note
us equiti top pick list updat januari
question management
numer compani meet take place san francisco next week assembl top list
question believ key discuss manag cover compani go
show co filg cf
fda requir addit preclinical/cmc data prior bla file slightli disappoint could
increment hurt avx sma competit posit though posit side high fda engag could
streamlin review process addit clinic data look support efficaci lower target
bcrx announc new rare diseas program enter preclin develop though still earli
stage illustr compani continu biolog medicin chemistri effort could enabl pipelin
diversif long-term around continu believ share price underappreci
clinic regulatori commerci prospect
celg acquisit impact biomedicinesa privat compani work reviv inhibitor sanofi
acquir targegen year ago scrap tox led fda clinic holdfor make
strateg sens help get celg myeloprolif disord space within heme/onc
limit presenc fedratinib truli past safeti uncertainti approv could worthwhil even
drug releg several-hundr million dollar jakafi failure/ineligible-pati marketgiven celg
leverag heme/onc salesforc still view rel modest impact deal continu believ
come bd front celg
even celg announc up-front payment impact bioscienc privat compani found
creator fedratinib inhibitor believ potenti jakafi competitor scrap year ago
sanofi due tox seek gain approv asset fda clinic hold even
formid compani like celg enter myeloprolif disord space without acquir
isnt necessarili posit see agent signific competit threat
jakafi franchis given jakafi market entrench physician/pati experi proven surviv benefit
well fedratinib safeti baggag instead would expect fedratinib primarili occupi non-overlap
nich market jakafi failure/inelig pt
weekend present addit ph data next-gen fxr agonist nash-tag
confer includ new detail highlight specif predict pk/pd profil dose
well biomark data ph result first top-lin around aasld believ detail data
continu support promis pbc nash movement ph ii indic though
ph ii start could see shift focu rsv asset year continu believ follow
appreci share better reflect valu hcv royalti portfolio
glpg toplin ph ib data early-stag osteoarthr continu support potenti reduc
cartilag breakdown oa would like requir lengthi larg develop program translat
symptomat radiograph benefit would need demonstr mechan novel
highlight pipelin program beyond cf tend get less valu continu progress well
continu believ share fairli reflect pipelin potenti
titl link note
happi set stage upsid posit ph iii
ip settlement
celg return execut print give clariti
lt momentum
rais signific upsid oppti
tidbit manag meet
tidbit manag meet
provid comprehens program updat morn program progress well track major
surpris notabl timelin set data creat potenti import
catalyst stock shift next-gen develop et alreadi telegraph continu view upsid
opportun signific given brexanolon long-term potenti depress disord
morn mru announc collabor simcer pharmaceut group joint develop three io
bispecif antibodi mru lead research discoveri program simcer pursu ind-en
studi see increment posit though clear whether meaning up-front payment
provid anoth partner addit help bring bispecif program line long-term world-wide
lend valid platform mru elig receiv upfront mileston program
progress develop cross-royalti arrang
major posit step forward aldr report posit data second ph iii studi lead drug eptinezumab
migrain see major efficaci safeti concern initi read conf call announc global
settlement cgrp ip teva two biggest overhang share remov see signific
appreci potenti grow enthusiasm cgrp space year believ share substanti
morn top acquisit impact celg report solid return core compet execut
in-lin reassur guid well increment encourag pipelin updat path confid
compani prepar revlimid cliff continu see share under-valued celg remain top
follow morn key de-risk event -- posit ph iii chronic migrain data teva ip settlement --
even confid probabl success long-term opportun lead drug eptinezumab increas target
particularli given today rel modest stock move see consider upsid potenti share
attend celg sell-sid meet sf increment addit tidbit beyond morn pre-report/guid pr
present continu see best-in-class near- long term growth opportun significantli
under-valued celg share
attend vrtx sell-sid manag meet san francisco compani press releas
updat last night contrast histor practic addit tripl data regulatori clariti pend near-
term takeaway mostli increment view continu point solid tez/iva launch expect
continu optim triple-combo remain bullish long-term cf leadership oper leverag
attend icpt sell-sid analyst meet sf felt management convey clear reassur messag
path restor growth ocaliva pbc confid nash opportun though still work done
came feel comfort label updat nash cirrhosi studi start potenti rx growth could turn
investor sentiment around nt drive upsid share label updat appear immin believ like
contain reason languag management re-affirmed guidanc updat ocaliva label note
word contempl thought ensur appropri dose monitor sever ill patient
still ensur patient physician also grasp potenti benefit though unclear whether would
box warn see materi either way compani maintain view label unlik
restrict also note adjud independ expert re-affirmed view ocaliva
titl link note
tidbit analyst breakfast
tidbit manag meet
takeaway management meet
takeaway manag meet
attend sell-sid breakfast host discuss center around sma competit bd
strategi well introduct new cfo season veteran appear strong addit
good fit came continu believ revenu setup look solid though could see increas focu
competit newsflow lt pricing/shar dynam could cap upsid especi given fewer potenti
attend gild sell-sid analyst event sf wednesday though compani mostli reiter
previous convey increment tidbit describ overal came continu
believ investor look favor recogn likelihood lt hiv domin
hcv becom increasingli stable/predict out-year growth opportun oncolog nash inflamm
progress drive appreci share
opportun meet glpg senior manag team week continu believ
cf program high risk progress rest pipelin includ filgotinib ipf program could help
draw attent portfolio asset believ could gener lt valu continu see share fairli
balanc risk reward
opportun meet senior manag yesterday overal major chang
tone messag would explain week stock downsid posit jakafi guidanc number
promis opportun pipelin continu see buy opportun given reward/risk ahead
biib/avx sma ip battl enta/gild hbv fxr oca
cancer aldr pacap
dive cover compani grant patent publish applic gain uniqu insight
priorit undisclos program life cycl strategi
updat model recent guidanc assum
coverag outperform rais pt
updat model incorpor heplisav launch
updat assum coverag op
wsj articl publish yesterday report celg talk acquir juno come surpris us
compani previous signal interest acquir ww right cellular therapi believ
potenti acquisit would enabl celg becom much competit cellular therapi space
see play key role futur oncolog help diversifi around revlimid patent cliff
adjust estim follow compani exondi sale guidanc subsequ meet
manag assum coverag outperform rate remov specul risk qualifi increas
price target see upsid potenti share believ crystal exondi strong launch
yield key clariti multipl underappreci long-term growth opportun eu exondi golo/casi gene tx
updat model heplisav-b launch mtg management assum coverag outperform
rate target see share under-valued long term given like low-risk steadi revenu stream
provid heplisav-b believ place valuat floor upsid opportun continu
look promis oncolog given heplisav-b approv reduc risk creat predict valuat floor
remov specul risk rate
though announc merger idera idra may surfac seem surpris given limit pipelin platform
overlap believ provid enhanc regulatori commerci experi within diversifi
combin compani framework help optim opportun lead asset prospect
recent led us upgrad share outperform synerg talent increas newsflow ultim
drive long-term valu deal structur effect pipelin combin idra ceo run new
titl link note
upsid lt pictur clearer
indic upsid number
out-licens non-cor asset increment
posit event
celg announc acquisit juno net view deal unsurpris strateg
import step compani maintain lt heme/onc leadership see accret begin
price quit high believ diversifi around revlimid patent cliff -- along
intern pipelin progress improv commerci execut improv sentiment drive upsid
today clinicaltri gov list show confirm clinic studi test agonist sd-
combo cancer termin patient due limit potenti
efficaci combin recal much lower-profil combo studi within dvax/mrk clinic
morn nv report earn eu jakavi revenu higher estim
growth translat estim jakafi royalti jakavi continu
show strong growth europ believ could also translat posit market suggest
potenti jakafi beat overal believ risk/reward upcom epcacadostat
readout increasingli attract given continu solid valuat foundat provid jakafi
gener posit ms sale fall mostli line expect ex-inventori benefit
stronger-than-expect ex-u spinraza growth help contribut top-lin beat -- guidanc
suggest potenti add growth overal noth quarter see chang percept
safe large-cap name though believ potenti long-term ms sma competit may
underappreci
morn announc would acquir oral sine compound one early-stag
pipelin asset al neurolog diseas up-front payment mileston
view increment posit monet asset receiv virtual attent
valu street continu like share event data year lead drug selinexor
celg alreadi pre-report provid guidanc given comprehens pipelin updat
recent full detail result report morn mostli increment provid add clariti
 /ex-u sale trend margin expect call focu driver diversif around revlimid
primarili recent juno acquisit highlight key new takeaway continu see potenti
sentiment celg shift back posit guidanc reaffirm potenti strong near-term
growth/execut pipelin develop support revenu sustain post-revlimid
celg previous report earn provid guidanc come today detail earn
call feel confid celg abil return execut best-in-class growth near-term preserv margin
medium-term diversifi around revlimid long-term expect street comfort element rebound
drive upsid level commensur strong fundament remain top pick
incorpor updat estim model new pt
solid revenu led stronger-than-expect ex-u spinraza growth good ms resili albeit help
one-tim factor along slightli better-than-expect guidanc perpetu view
safe larg cap still potenti competit headwind binari adu data approach nearer
believ signific bd initi diversifi lt revenu becom increasingli import see fairli
balanc reward/risk price target increas model updat
titl link note
develop partner competitor dmd
hcv earn posit indic market
preview potenti scenario ocaliva label updat
settl abraxan ip lt gener would still need
morn partner summit therapeut read interim ph ii result ezutromid dmd
demonstr increas utrophin level like earli draw definit conclus separ
competitor solid bioscienc disclos fda place microdystrophin gene therapi program
partial clinic hold -- could extend srpt/nch lead time microdystrophin gene therapi
program though degre highlight challeng success develop disease-modifi
treatment dmd view net posit whose valuat believ fulli reflect
potenti exondi broader dmd pipelin
report strong hcv earn particularli strong ex-u uptak view
indic hcv market stabil revenu patient flow predict posit
go earn help put recent fear hcv earn miss rest addit
benefit strong mavyret/maviret launch anticip royalti higher
label updat ocaliva address dosing/safeti concern expect immin number
scenario could play discuss detail overal believ new label like
instruct restrict enabl continu bounceback ocaliva pbc rx/uptak provid
valuat floor set appreci nash result
assum coverag updat model includ probability-weight royalti follow
initi data reflect recent guidanc price target increas remov
specul risk flag given two solid dmd launch believ recent stock price appreci better
captur lt opportun emflaza translarna sma promis lt platform product balanc
finit lifecycl clinic risk maintain sector perform
friday night celg announc settlement patent litig actavis/teva allow potenti gener
abraxan onto market start march current model abraxan revenu maintain
remov lt abraxan sale would reduc dcf-base valuat howev import
note even gener longer block enter market start would still need
overcom could high regulatori hurdlemanufactur bioequival gener abraxan
particularli complex particl size paclitaxel/albumin ratio etc caus variabl physiochem attribut
weekend first clinic data present roche/ptc oral slice modul sma
opportun review present speak management extens
fwp decis expect valuat
note today fwp announc epo revok eu patent line expect
impact valuat recal previous settl fwp secur s/eu tecfidera ip
posit tecfidera ip maintain variou legal proceed gain licens fwp
ip thu longev tecfidera franchis longer jeopardi addit eu proceed relat
fwp ip larg determin whether owe fwp increment royalti addit
settlement sinc fwp eu patent revok assum like appeal decis maintain result
owe royalti note assum royalti gain potenti patent life use
fwp vs ip essenti neutral impact valuat assum tecfidera goe gener eu
begin expir na exclus
titl link note
rsv highlight san-ablynx call drum interest
add recent mavyret momentum
recent rise share larg due strength mavyret anticip higher
expect hcv royalti partner abbv earn call friday also note potenti addit
momentum come increas interest earli stage rsv program part result posit
indic read today sanofi-ablynx deal note call highlight ablynx mid-stag anti-rsv
nanobodi conjunct sanofi rsv mab well unmet need current space earli
comparison believ enta potent non-fus inhibitor rsv-a rsv-b activ
remain interest asset strong potenti rsv though current model expect
program receiv increas attent year though current level believ share better reflect
potenti mavyret royalti pipelin
spent time senior manag discuss compani commerci plan
brexanolon pivot plan begin crystal come meet continu see
substanti opportun sever near-term catalyst insonmia data brexanolon filing/approv
could reaffirm larg market opportun could transform long termand drive addit
morn signific new articl co-author gene therapi kol dr jame wilson publish on-line
describ sever neurological/liv toxic multipl anim speci receiv high-dos system sma-
focus gene therapi sever compani develop gene therapi neurolog diseas discuss
articl potenti implic avx
exhibit stock cover kennen mackay
titl link note
fear faer zejula ae updat spark tsro
fda advers event report faer public dashboard report real world ae case zejula
includ death zejula common nausea report thrombocytopenia report
fatigu report line trial though nausea fatigu proport higher vs
thrombocytopenia real world dataset
move clinic though efficaci evalu may need wait target popul today
market close announc ind applic submit decemb
trial expect initi plan initi trial asset remain
upsid valuat trial includ dose escal phase determin assess
safeti pk follow dose expans phase evalu orr safeti pk advanc breast
ovarian endometri urotheli cancer initi target indic trial first-in-class
i/o afucosyl monoclon antibodi demonstr potent antibody-depend cell-medi
cytotox cell checkpoint blockad activ vitro dose-depend anti-tumor efficaci vivo
express multipl tumor type includ breast ovarian endometri cancer yet
address anoth i/o drug
morn announc posit result japanes trial vadadustat dialysi depend
chronic kidney diseas dd-ckd line prior studi expect patient trial met primari
endpoint mean hb chang baselin week vadadustat group demonstr signific
improv vs placebo mg mg mg dose group press
releas void actual hb chang well baselin characterist though convers management
follow press releas suggest popul could anticip line japanes ckd
demograph vs us older lower less diabet less sever inflamm etc vadadustat
continu appear safe common report nasopharyng diarrhea
headach drug-rel sae report sae patient incid ae vadadustat
group mg mg mg placebo respect vs
report ndd-ckd trial japan septemb also met primari endpoint mean hb
chang baselin dose-depend respons observ
morn announc amend protocol combo trial cabozantinib
atezolizumab local advanc metastat solid tumor includ four new expans cohort ad nsclc
castration-resist prostat cancer two new indic beyond rcc uc origin protocol
trial start recruit juli though septemb list start date whether initi respons
inform expans decis ahead look data unknown
pipelin expand start
 ind start
japan reaffirm vada effect dialysi
depend ckd continu track
atezo expand protocol unexpect
posit combo trial includ nsclc
titl link note
xgeva expand label treatment mm
bone lesion could drive upsid estim
cemiplimab dupi key focu expans
though sni lock unlock fund develop
myopathi strength key
disappoint investor
expand pipelin cabo asco-gi
takeaway morn amgn/fda announc approv xgeva denosumab sbla expand usag
prevent skeletal-rel event bone metastas solid tumor includ multipl myeloma mm
project us xgeva growth ww sale line consensu
continu monitor prescrib trend mm determin whether earli approv could drive growth beyond
st estim note xgeva previous mm treatment guidelin view approv
ad larg market xgeva mm patient present skelet lesion patient develop
bone lesion throughout cours diseas melton lj et al bone miner
multipl myeloma patient experi patholog fractur cours diseas xgeva
could add benefit approv come ahead feb pdufa date base studi
xgeva demonstr non-inferior nvss zometa zoledron acid prevent skeletal-rel event
adult patient newli diagnos multipl myeloma bone diseas
takeaway today regn/sni announc expand acceler develop plan cemiplimab dupilumab
addit fund direct toward cemiplimab view expand fund posit warrant
though expect investor sentiment temper disclosur regeneron grant limit waiver
